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Multisystem autoimmune disease caused by
increased STAT3 phosphorylation and dysregulated
gene expression
Signal transducer and activator of transcription (STAT)
3 is a member of the STAT family, and plays a major role
in various immunological mechanisms.1 Mutations in
STAT3 are associated with a broad spectrum of manifes-
tations, including immunodeficiency, autoimmunity, and
malignancy.2 In particular, heterozygous germline loss-of-
function (LOF) mutations cause Hyper-IgE syndrome
(HIES),3-5 while heterozygous germline gain-of-function
(GOF) mutations have recently been associated to multi-
organ autoimmune manifestations (i.e. type 1 diabetes,
enteropathy, cytopenia, interstitial lung disease,
hypothyroidism), lymphoproliferation, short stature, and
recurrent infections (OMIM #615952).6-8 
We report a 7-year-old boy who presented with early-
onset severe enteropathy, and diffuse eczematous der-
matitis since birth. During the first weeks of life,
Hirschsprung disease was also suspected and surgically
treated. Gastrointestinal and cutaneous manifestations
were first ascribed to food allergy with quite a good
response to amino acid-based formula. In the following
months, the patient failed to thrive, and developed respi-
ratory tract infections. At two years, the patient present-
ed with progressive interstitial lung disease characterized
by lymphocytic interstitial infiltration leading to pul-
monary hypertension, tricuspid insufficiency, and right
ventricular heart failure with hepatomegaly. Because of
the increased risk of infections, he received intravenous
(IV) immunoglobulin infusions (400 mg/kg), prophylaxis
with cotrimoxazole and fluconazole.
Methylprednisolone at 0.3 mg/kg/day was also given to
treat autoimmune manifestations.
Later, growth hormone (GH) deficiency, hypothy-
roidism and type 1 diabetes were diagnosed. 
Informed consent was obtained from the patient’s par-
ents. Ethical approval was obtained by the Institutional
Review Board of Spedali Civili of Brescia. Genomic DNA
was extracted from peripheral whole blood, whole
exome sequencing (WES) was performed while the iden-
tified mutation was validated by Sanger sequencing.5
STAT3 phosphorylation was analyzed by flow cytometry
on whole blood after stimulation with interferon (IFN)-α
(40,000 U/mL) or interleukin (IL)-27 (100 ng/mL) for 30
minutes (min) according to Becton Dickinson protocol:
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Figure 1. STAT3 phosphorylation and chromatin immunoprecipitation assay in the STAT3 gain-of-function (GOF) patient. (A) STAT3 phosphorylation in T cells
(CD3+ cells) in response to interferon-α (IFNα) and IL-27 stimulation or medium alone. Cells from whole blood samples were lysed, fixed and permeabilized, then
stained with anti-p-STAT3 and anti-CD3 antibodies. Extent of p-STAT3 is shown on y-axis as mean fluorescent intensity. (B) Time course of STAT3 phosphorylation
of Epstein-Barr virus (EBV)-transformed B-cell lines obtained from a control subject or from the STAT3 GOF patient. Cells were kept in culture with serum free
medium overnight and stimulated with IFNα for 15, 30, 60, 90 or 120 minutes. Then, cells were permeabilized and stained with anti-p-STAT3. Extent of p-STAT3
is shown on y-axis as mean fluorescent intensity. (C) Western blot analysis of STAT3 tyrosine phosphorylation in EBV-transformed B-cell lines from a control sub-
ject or from the STAT3 GOF patient. Cells were kept in culture with serum free medium overnight and then either untreated or stimulated with IL-6 (200 ng/mL)
and IL-10 (200 ng/mL) for 30 minutes. (D) Evaluation, by chromatin immunoprecipitation analysis, of STAT3 recruitment to the SOCS3, SBNO2, IL-10 and PRL
promoters of EBV-transformed B cells cultured in the presence or absence of IL-6 (200 ng/mL) and IL-10 (200 ng/mL) for up to 1 hour. Co-immunoprecipitated
DNA was expressed as percent of the total input. Error bars represent standard errors calculated from triplicate quantitative polymerase chain reactions.
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cells were acquired using FACSCalibur (BD Bioscence)
and analyzed by FlowJo version 7.5 Software (TreeStar).
Epstein-Barr virus (EBV)-immortalized B cells western
blot assay was performed after overnight starvation, as
previously described.5
Reverse transcription quantitative real-time poly-
merase chain reaction (RT-qPCR) was performed with
specific probes (Applied Biosystems) on CFX96 RT
System (BIO-RAD). EBV cells were stimulated with 200
ng/mL of IL-6 or IL-10 for 1 hour (h) with/without
overnight starvation. Results are shown as mean normal-
ized expression (MNE) units after GAPDH normalization.
Chromatin immunoprecipitation (ChIP) assay was per-
formed on 5x106 EBV-transformed cell lines stimulated
with IL-10 or IL-6 for 45 min and executed as described.9
To establish the background levels of ChIP experiments,
STAT3 was quantified also at the promoter of prolactin
(PRL) since it is completely silent in leukocytes.
Because of the association of severe early-onset
enteropathy and autoimmune manifestations, immunod-
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Figure 2. Analysis of STAT3, IL10, BCL3, IL2RA, and SOCS3 mRNA expression in Epstein-Barr virus (EBV)-transformed B-cell lines. (A-E) EBV-transformed B cell
lines from two healthy donors or the STAT3 gain-of-function (GOF) patient were kept overnight in serum-free medium and then either untreated or stimulated for
1 hour with IL-6 (200 ng/mL) and IL-10 (200 ng/mL) to investigate STAT3, IL10, BCL3, IL2RA, and SOCS3 mRNAs by RT-qPCR. (F) Western blot analysis of STAT1
and STAT2 levels in cytoplasmic extracts from EBV-transformed B cells from a control subject or the STAT3 GOF patient. Cells were cultured overnight without
serum and then stimulated with IFNα (1000 U/mL) for 30 minutes. Levels of p-STAT1, p-STAT2, total STAT1 and STAT2 in the cytoplasmic fractions were evaluated.
Samples were also immunoblotted for tubulin, a cytoplasmic marker.
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eficiency polyendocrinopathy enteropathy X-linked
(IPEX) syndrome or other IPEX-like inherited disorders
were suspected. But the search for mutations in FOXP3,
CD25 and STAT5b resulted negative.10,11 Subsequently,
WES was performed and a de novo heterozygous mis-
sense STAT3mutation was identified that clustered in the
DNA-binding domain and caused methionine-to-arginine
substitution (c.1986T>G) at position 329 (p.M329R).
Lymphocyte subsets analysis revealed normal levels of
regulatory (CD4+ CD25hi FOXP3+) and effector
(CD45RA–CCR7–) CD3+T lymphocytes.
STAT3 activation in response to cytokines such as IL-6,
IL-10, IL-21, IL-23 and IFN-α is characterized by phos-
phorylation of tyrosine 705 (pY705) by associated Janus
activating kinases (JAK) and subsequent STAT–STAT
dimerization and nucleus translocation.12 We compara-
tively evaluated by ELISA assay plasmatic cytokines con-
centration in the patient and in age-matched healthy
donors. Detectable levels of IL-6 (72.04 pg/mL), IL-10
(32.5 pg/mL), and IL-17(55.82 pg/mL) were observed in
the patient, but not in the healthy donors (data not
shown). The flow cytometry analysis of CD3+ lympho-
cytes showed detectable levels of STAT3 phosphoryla-
tion (pSTAT3) in the patient, but not in healthy donors.
Increased pSTAT3 levels were observed both in unstimu-
lated conditions and after IFN-α or IL-27 stimulation
(Figure 1A).
Next, we analyzed STAT3 phosphorylation in unstim-
ulated cells or after 15, 30, 60, 90 and 120 min after stim-
ulation of EBV-transformed cell lines with IFN-α (20,000
U/mL). The patient showed a delayed dephosphorylation
of STAT3, especially 90 min after stimulation (Figure 1B). 
Finally, we investigated the levels of pSTAT3 by west-
ern blot assay in unstimulated cells, and following IL-6 or
IL-10 stimulation in EBV-transformed cell lines. Analysis
of cells derived from the patient with GOF mutation
showed detectable levels of pSTAT3 also in unstimulated
conditions, which increased after IL-6 (200 ng/mL) or IL-
10 (200 ng/mL) stimulation. This was associated with
increased levels of STAT3 protein as compared to the
healthy subjects (Figure 1C). 
In order to evaluate STAT3 binding capacity to specific
DNA sequences involved in the regulation of inflamma-
tion and immune response (e.g. SOCS3 and SNBO2), we
performed a ChIP assay in EBV-transformed cells from
the patient with STAT3 GOF mutation and from a
healthy subject. We observed that unstimulated cells
from the patient showed enhanced STAT3 binding to
SOCS3 and SBNO2 promoters. But after stimulation with
IL-6 or IL-10, STAT3 binding was weakly increased as
compared to cells from healthy controls (Figure 1D). 
Moreover, we evaluated the expression of STAT3, IL-
10, BCL-3, IL2RA and SOCS3 mRNAs by -RT-qPCR.
Analysis of mRNAs in unstimulated cells from the patient
showed high-level expression of STAT3, IL-10, BCL-3,
IL2RA, and SOCS3 at baseline, and further increase of
SOCS3 and IL10 mRNAs after stimulation with IL-6 or
IL-10, while cell starvation did not influence the extent of
gene expression in the cells of the patient (Figure 2A-E).
Patients with GOF-STAT3 mutation share similar phe-
notypic manifestations (i.e. eczema, autoimmunity) with
STAT5b deficient patients,13 suggesting that STAT pro-
teins phosphorylation and expression can be negatively
regulated by STAT3-mediated induction of SOCS3.14
Therefore we investigated cytokine-induced phosphory-
lation of both STAT1 and STAT2, and the expression of
the total amount of STAT1 protein in the EBV-trans-
formed cell line from the patient with STAT3 GOF muta-
tion and from a healthy subject.
After preparation of cytoplasmic extracts, we observed
that STAT2 phosphorylation levels were lower in STAT3-
mutated cells after IFNα stimulation, as compared to
healthy control. In contrast, the level of phosphorylated
and total STAT1 was similar in both control and patient
EBV-transformed cell lines (Figure 2F). These results sug-
gest that the STAT3 GOF mutation p.M329R affects not
only STAT3 but also STAT2-mediated response. 
Immunological studies in this patient revealed normal
T-cell subsets but severe depletion of both plasmacytoid
(BDCA2+/CD123+/CD4+) and myeloid dendritic
(CD1c+/CD4+/CD19–/CD14–) cells: pDC 0.06%, mDC
0.05% of total peripheral blood mononuclear cells
(PBMC) as compared to healthy subjects (pDC n.v. 0.16-
0.7%, mDC n.v. 0.18-0.92%). This is in contrast with
two other cases that showed increased T-effector cell
counts and a reduction of T-regulatory cells,1,15 but these
differences might be related to inter-individual variations.
Moreover, high plasmatic concentrations of IL-6, IL-10
and IL-17 in this patient were also observed, suggesting
that these cytokines might be involved in the mechanism
of the autoimmune diseases. All these atypical immuno-
logical features are probably related to the novel STAT3
mutation that was associated with increased phosphory-
lation of STAT3, while most of patients with STAT3 GOF
mutations display normal STAT3 phosphorylation, but
abnormal gene regulation.7
Current therapies for multiple organ autoimmune dis-
eases in patients with STAT3 GOF mutations include
immunosuppressive drugs and hematopoietic stem cell
transplantation in selected patients.16 Because tyrosine
kinases inhibitors, such as ruxolitinib, have been exten-
sively used in conditions characterized by abnormal
STAT activation, their use could be favorably extended to
immunological diseases associated with increased STAT3
phosphorylation, such as observed in this case.17
Francesca Todaro,1,2* Nicola Tamassia,3* Marinella Pinelli,1,2
Daniele Moratto,1 Laura Dotta,1 Alessia Grassi,4
Filippo Consonni,1 Mauro Giacomelli,1 Paolo Lionetti,5
Elisa Gardiman,3 Marco A. Cassatella,3 Eleonora Gambineri,4
Roberto Berni Canani6** and Raffaele Badolato1**
*FT and NT contributed equally to this work. **RBC and RB
contributed equally to this work as senior authors.
1Clinica Pediatrica and “A. Nocivelli” Institute for Molecular
Medicine, Department of Clinical and Experimental Sciences,
University of Brescia, Spedali Civili Hospital, Brescia; 2Dottorato di
Ricerca in Scienze della Riproduzione e dello Sviluppo, University of
Trieste, Trieste; 3Department of Medicine, Division of General
Pathology, University of Verona, Verona; 4Department of Experimental
and Clinical Medicine, University of Florence, Florence; 5Department of
'NEUROFARBA', Section of Child's Health, University of Florence
and Anna Meyer Children's Hospital, Florence and 6Department of
Translational Medical Science, and CEINGE Advanced
Biotechnologies, and European Laboratory for the Investigation of Food
Induced Diseases, and Task Force on Microbiome Investigations,
University of Naples Federico II, Naples, Italy
Correspondence: RAFFAELE BADOLATO.
raffaele.badolato@unibs.it. 
doi:10.3324/haematol.2018.202374
Funding: this work was supported in part by Ministero della Salute
(grant n. NET-2013-02355002) to RB.
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online version
of this article at www.haematologica.org.
References
1. Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of
haematologica 2019; 104:e324
CASE REPORTS
Jak/STAT Signaling in Immunity and Disease. J Immunol. 2015;
194(1):21-27.
2. Forbes LR, Milner J, Haddad E. Signal transducer and activator of
transcription 3: A year in review. Curr Opin Hematol. 2016;23(1):23-
27.
3. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 Mutations in the
Hyper-IgE Syndrome. N Engl J Med. 2007;357(16):1608-1619.
4. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative muta-
tions in the DNA-binding domain of STAT3 cause hyper-IgE syn-
drome. Nature. 2007;448(7157):1058-1062.
5. Giacomelli M, Tamassia N, Moratto D, et al. SH2-domain mutations
in STAT3 in hyper-IgE syndrome patients result in impairment of IL-
10 function. Eur J Immunol. 2011;41(10):3075-3084.
6. Haapaniemi EM, Kaustio M, Rajala HLM, et al. Autoimmunity,
hypogammaglobulinemia, lymphoproliferation, and mycobacterial
disease in patients with activating mutations in STAT3. Blood. 2015;
125(4):639-648.
7. Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation
and autoimmunity caused by germline STAT3 gain-of-function
mutations. Blood. 2015;125(4):591-599.
8. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline
mutations in STAT3 cause early-onset multi- organ autoimmune dis-
ease. Nat Genet. 2014;46(8):812-814.
9. Tamassia N, Castellucci M, Rossato M, et al. Uncovering an IL-10-
dependent NF-κB recruitment to the IL-1ra promoter that is impaired
in STAT3 functionally defective patients. FASEB J. 2010;24(5):1365-
1375.
10. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked syndrome: A paradigm of
immunodeficiency with autoimmunity. Front Immunol. 2012;
3(JUL):1-25.
11. Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an
evolving web of heritable autoimmune diseases. Curr Opin Pediatr.
2013;25(6):708-714.
12. Lorenzini T, Dotta L, Giacomelli M, Vairo D, Badolato R. STAT
mutations as program switchers: turning primary immunodeficien-
cies into autoimmune diseases. J Leukoc Biol. 2017;101(1):29–38.
13. Kanai T, Jenks J, Nadeau KC. The STAT5b Pathway Defect and
Autoimmunity. Front Immunol. 2012;3:234.
14. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in
T cell differentiation, maturation, and function. Trends Immunol.
2009;30(12):592-602.
15. Consonni F, Dotta L, Todaro F, Vairo D. Signal transducer and activa-
tor of transcription gain-of-function primary immunodeficiency/
immunodysregulation disorders. Curr Opin Pediatr. 2017;29(6):711-
717.
16. Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in
Human Disease. J Clin Immunol. 2015;35(7):615-623.
17. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT
signalling for human diseases. Nat Rev Drug Discov. 2013;12(8):611-
629.
haematologica 2019; 104:e325
CASE REPORTS
